Drawing for GROVECKLY

USPTO serial 88360445

GROVECKLY

Reviewed by CopyMark Law Group

Reg. 6203151Status 700Renewal
Filing date
Status date
Registration date
Nov 24, 2020
Examiner
LORENZO, GEORGE M
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with GROVECKLY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $975

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Shannon Marie McKeon

Shannon Marie McKeon DYKEMA GOSSETT PLLC1301 K STR., N.W., SUITE 1100WASHINGTON, DC 20005UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of growth disorders, pharmaceutical preparations for the treatment of endocrine disorders, pharmaceutical preparations for the treatment of bone disorders, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations for the treatment infectious diseases; diagnostic preparations for medical use, namely, diagnostic preparations for identifying and detecting growth hormone deficiency, endocrine disorders, bone disorders, cancer, and infectious diseasesACTIVE—
009Downloadable computer software and downloadable computer programs for use in providing medical advice and advice on medications for treatment, patient assistance and health insurance in the field of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for sharing information related to growth disorders, endocrine disorders, bone disorders, cancer, infectious diseases and the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases for use by patients with growth hormone disorders, hypoparathyroidism, skeletal dysplasia, and diabetes in the medical field of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; downloadable computer application software for mobile phones, tablet computers handheld computers and personal computers, namely, downloadable software that coordinates the delivery of health care services between health care providers, patients and those parties responsible for the payment of health care services, namely, downloadable software that allows individuals seeking medical education, information and services to locate a physician and treatment facility in their geographic area for medical treatment and allows physicians and health care professionals to communicate their credentials and specialization to patients and parties responsible for payment of healthcare services; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, downloadable software that enables health care providers to monitor patients, communicate clinical information relevant to a patient's care, provide and exchange information concerning patients and the health care services provided to patients; downloadable software, downloadable software applications and downloadable mobile applications for providing co-pay and other financial or medical access support; downloadable computer software for providing a communications platform enabling users to share health and healthcare information; downloadable software, downloadable software applications and downloadable mobile applications for the measurement of height, weight, blood pressure, serum calcium, blood glucose, and heart rate; downloadable software, downloadable software applications and downloadable mobile applications for providing, exchanging, retrieving and analyzing health and healthcare information; downloadable software for medical purposes, namely, for formatting, viewing and transmitting medical data collected and stored on hormone injection pens and pumps and between said injection pens and pumps and portable electronic devices; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for providing healthcare-related information, medication reminders, and tracking medication dosing history; the foregoing downloadable software related to pharmaceutical preparations for the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseasesACTIVE—
010Medical devices for injection, dosage and control of pharmaceuticals, namely, medical devices for injection, dosage measurement and monitoring of pharmaceuticals for the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; syringes for medical purposes and for injections; syringes for injection for medical and surgical use, namely, syringes in the form of pens for surgical use; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with management of growth hormone disorders, hypoparathyroidism, skeletal dysplasia, cancer and diabetes; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus for diagnostic purposes, namely, medicine dosage dispensers containing software featuring web-based medical information for physical and psychological examination and assessment of patients remotely and at a clinic; dosage management dispensers containing software for medical information management for guidance and control of medicines and for therapeutic use in web-based physical and psychological examination and assessment of patients remotely and at a clinicACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 24, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Nov 24, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 16, 2020DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Oct 16, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 27, 2020IUCNNOTICE OF ALLOWANCE CANCELLED—
Aug 27, 2020EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Jun 4, 2020DOCKASSIGNED TO EXAMINER—
Apr 7, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 11, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 11, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 22, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 8, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 7, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 7, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 7, 2020ALIEASSIGNED TO LIE—
Dec 16, 2019ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jun 12, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jun 12, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Jun 12, 2019CNSLSUSPENSION LETTER WRITTEN—
Jun 12, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Jun 12, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 12, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 12, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 11, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 11, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 11, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2019DOCKASSIGNED TO EXAMINER—
Apr 15, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 1, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance